Moderna Inc News - MRNA

	Real-time Prices	Level 2
Canadian Securities Exchange

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma PR...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

U.S. Futures Rise as Investors Await Fed Rate Decision; Oil Prices Drop

U.S. index futures rose in Thursday’s pre-market session following Donald Trump’s victory, which sent...

Trump Media Shares Surge 32% Pre-Market; Tesla Jumps 13%; Coinbase Rises with BTC All-Time High

Trump Media & Technology Group (NASDAQ:DJT) – Donald Trump’s media company reported a $19.2 million...

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at...

Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program, as the third Phase 3 trial for the...

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and...

Form 4 - Statement of changes in beneficial ownership of securities

Shareholders of Moderna, Inc. Should Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights - MRNA

Shareholders of Moderna, Inc. Should Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights...

axelvento 4 days ago

NEXT> Why a teenager’s bird-flu infection is ringing alarm bells for scientists

https://www.nature.com/articles/d41586-024-03805-4

👀 1 👍️ 1

axelvento 6 days ago

Johns Hopkins surgeon Makary is Trump’s pick to lead FDA "pro-vaccine"

https://www.healthcaredive.com/news/trump-fda-martin-makary-surgeon-nominate/733829/

👌 2 👍️ 1

reyprimero 1 week ago

Mrna undervalued a lot, time to load the truck, IMO

👍️ 2 💯 3

Vexari 1 week ago

Manipulation is key

To the equation

👎️ 1 🗑️ 1 🚽 1 🤪 1 ⤵️ 1

axelvento 1 week ago

Our question is, what data is Mr. Kennedy talking about? Comprehensive national vaccine safety data are readily available to anyone. This includes the safety data used to license vaccines and data gathered after they have gone into use

https://www.nytimes.com/2024/11/20/opinion/rfk-jr-vaccines-public-health.html

$MRNA

👍️ 2 😄 1

axelvento 2 weeks ago

HSBC upgrades to Buy on underestimated pipeline potential

👍️ 2 🤙 1

axelvento 2 weeks ago

Trump gives RFK Jr McDonald’s ‘poison’ to eat on private plane

https://www.yahoo.com/news/trump-gives-rfk-jr-mcdonald-133657991.html

👍️ 1 😴 1 🤣 1

axelvento 2 weeks ago

Bears need to take into consideration the CMV data coming our this quarter. It's a 3-5 TAM drug with no competitors
I'd be careful shorting this right now!

👍️ 1

Stock Guy777 2 weeks ago

Amen to that!

👍️0

axelvento 2 weeks ago

Kennedy’s spokesperson did not respond to my request for comment last night as to whether, as HHS secretary, RFK Jr. would move to outlaw any existing vaccines, and referred me to his victory-lap post on X, which did not mention the topic

https://www.theatlantic.com/politics/archive/2024/11/trump-health-human-services-nomination/680674/

clown-

👍️0

axelvento 2 weeks ago

I agree$$$$$$$$

👍️0

DewDiligence 2 weeks ago

He won't be confirmed by the Senate, in my opinion.

👍️ 2 🙏 1 🤞 1

Stock Guy777 2 weeks ago

By the looks of the chart it has been finished! This thing was well into the 300s when I traded it from $80’s to 300+ and now look at it!! Look Out below! Just decided to come back and take a look. It’s obviously done horrible as did the” Shot”

👍️ 1

Bountiful_Harvest 2 weeks ago

Vaccine Stocks Slide Further After Trump Taps RFK Jr. To Lead HHS; CNN Outraged

https://www.zerohedge.com/markets/vaccine-stocks-slide-further-after-trump-taps-rfk-jr-lead-hhs

Moderna is finished...

👍️ 1

Stock Guy777 2 weeks ago

Yeah, good for you. I played this back in the day. And got out. I was never a fan, just knew before the actual vaccine was created, that it would run up.

👍️0

Stock Guy777 2 weeks ago

Yeah, for the better! Finally stopping these Frankenstein doctors and their controversial “shots” that play havoc on your whole body that I believe potentially killed my father early

👍️ 1

spartex 2 weeks ago

Well right now it is having a huge impact on MRNA longs that are deeply under water if they haven't hedged with puts.

A four year low going all the way back to April 2020 period. Brutal. Glad I alerted the troops on this news yesterday to save themselves 7% or more downward draft today!

👍️0

axelvento 2 weeks ago

Trump’s latest controversial Cabinet pick could have a huge impact on Americans’ health and lives
https://edition.cnn.com/2024/11/15/politics/trump-rfk-cabinet-pick-american-health-analysis/index.html

the game$$$$$$$

👍️ 1 🤟 1

axelvento 2 weeks ago

RFK Jr. has built a reputation as a vaccine skeptic but has stopped short of adopting the “anti-vaxx” label attributed to him by critics. The former environmental lawyer has said his children are vaccinated and that he does not oppose safe vaccines.

relax$

👍️ 1 😃 1

axelvento 2 weeks ago

Kennedy has been one of the country’s most prominent anti-vaccine conspiracy theorists for years and has frequently spread falsehoods about the safety and efficacy of vaccines. Last week, Kennedy said he would “immediately” begin studying vaccine safety and efficacy but promised to not “take vaccines away from anybody.”

👍️0

Bountiful_Harvest 2 weeks ago

Shares of $MRNA and other hot shot stocks in full collapse on news of RFK joining the Trump admin

👍️0

spartex 2 weeks ago

Big selling all of a sudden. Sub $40 now. 52 week low.

Appears that Trump will nominate Rfk Jr. to Health and Human Services Admin.

https://www.politico.com/news/2024/11/14/robert-f-kennedy-jr-trump-hhs-secretary-pick-00188617

😜 1

axelvento 2 weeks ago

next-
https://www.theguardian.com/society/2024/oct/23/doctors-trial-worlds-first-vaccine-against-vomiting-bug-norovirus

👍️ 4 🔜 1

Vexari 2 weeks ago

The majority shareholder of Moderna is?

When you are suffering

They are profiting

👇️ 1 🗑️ 1 🚽 1 🤪 1 🧻 1

axelvento 3 weeks ago

https://www.biospace.com/job-trends/biospace-announces-2025-best-places-to-work-in-biopharma

👋 1 👍 1

axelvento 3 weeks ago

Jpmorgan Chase & Co ownership in MRNA / Moderna, Inc.
On November 8, 2024 - Jpmorgan Chase & Co filed a 13F-HR form disclosing ownership of 2,227,044 shares of Moderna, Inc. (US:MRNA) valued at $148,833,351 USD as of September 30, 2024. The entity filed a previous 13F-HR on August 12, 2024 disclosing 1,756,708 shares of Moderna, Inc.. This represents a change in shares of 26.77% during the quarter. The current value of the position is $104,292,471 USD.

https://fintel.io/so/us/mrna/jpmorgan-chase-

👍 2

axelvento 3 weeks ago

https://www.acsh.org/news/2024/11/07/dont-be-afraid-mrna-vaccines-49111

👍️ 3 🤙 1

axelvento 3 weeks ago

Moderna Buys Norwood Campus for $400M

https://bankerandtradesman.com/moderna-buys-norwood-campus-for-400m/#:~:text=Lab%20developer%20Alexandria%20Real%20Estate,core%20properties%20in%20Greater%20Boston.

👍️ 3 😀 1

axelvento 3 weeks ago

Moderna (MRNA) Q3 2024 Earnings Call Transcript

https://www.fool.com/earnings/call-transcripts/2024/11/07/moderna-mrna-q3-2024-earnings-call-transcript/

👍️ 4 ✌️ 1

EarningsCentral 3 weeks ago

👍️0

axelvento 4 weeks ago

MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $1.25 billion and a loss of $1.91 per share, respectively

👍️0

axelvento 1 month ago

Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

https://investors.modernatx.com/news/news-details/2024/Merck-and-Moderna-Initiate-Phase-3-Trial-Evaluating-Adjuvant-V940-mRNA-4157-in-Combination-with-KEYTRUDA-pembrolizumab-After-Neoadjuvant-KEYTRUDA-and-Chemotherapy-in-Patients-With-Certain-Types-of-Non-Small-Cell-Lung-Cancer-NSCLC/default.aspx

huge news$

👍️ 1 🤑 1

axelvento 1 month ago

https://www.investing.com/news/company-news/piper-sandler-maintains-overweight-rating-on-moderna-stock-93CH-3680972

👋 1 👍️ 2

axelvento 1 month ago

20B market cap, 10B in cash, high potential pipeline in 4 therapeutic areas!

👍️ 2 💪 1

axelvento 1 month ago

Moderna has a whopping 33 million short share interest, but daily volume now a paper-thin 3.7 million

"Highest shorted stock on S&P500"

👍️ 1 🤣 1 ☝️ 1

axelvento 1 month ago

MRNA December 6th Options Begin Trading

https://www.nasdaq.com/articles/mrna-december-6th-options-begin-trading

👍️0

axelvento 1 month ago

Moderna’s norovirus vaccine enters Phase III trials in the UK
The firm hopes to file marketing applications in 2026 to have the vaccine approved by health regulators.

https://www.clinicaltrialsarena.com/news/modernas-norovirus-vaccine-enters-phase-iii-trials-in-the-uk/

👍️ 2 🤙 1

Vexari 1 month ago

Depends

On the road

That they're on

👎️ 1 🗑️ 1 🚽 1 🧻 1 0️⃣ 1

Vexari 1 month ago

All that is marketed

Is fear based

🌬️ 1 🎃 1 👎️ 1 🕳️ 1 🗑️ 1

gapole 1 month ago

looks like meltdown here. where is the bad news? $53.54

👍️0

Monksdream 1 month ago

MRNA new 52. Week low

👍️0

axelvento 1 month ago

Moderna stock touches 52-week low. bouncer

👍️0

axelvento 1 month ago

https://www.kcl.ac.uk/news/mrna-cancer-vaccine-potential-advanced-stage-cancer-patients-in-phase-1-trial

👍️ 1 ✌️ 1

jondoeuk 1 month ago

I couldn't find a PR or the poster.

👍️0

Vexari 2 months ago

Unraveling all the Lies of the Covid-19

Psychological Operation

👎️ 2 🗑️ 1 😎 1 🤥 1 🧻 1 0️⃣ 1

axelvento 2 months ago

$MRNA We are tackling cancer on an individual basis where we can take samples from each patient, understand their cancer, and design a therapy specifically for them

https://www.fastcompany.com/91202048/the-mrna-advantage

👍️ 1 🫨 1 ☝️ 1

tmonkey 2 months ago

this one near a bottom-im in------tmonkey

👍️0

axelvento 2 months ago

https://www.globenewswire.com/news-release/2024/10/04/2958235/0/en/Global-mRNA-Cancer-Vaccine-Clinical-Trial-FDA-Approval-Market-Size-Future-Opportunity-Companies-Insight.html

$MRNA

👍️ 1 🤑 1

axelvento 2 months ago

Join us on Nov 8, as we, alongside
moderna_
, share promising data on anti-GPC3 in vivo CAR-M therapy for HCC. We'll also present TIP poster for the Ph1 study of anti-HER2 CAR-Monocytes targeting solid tumors.

https://ir.carismatx.com/news-releases/news-release-details/carisma-therapeutics-announces-upcoming-presentations-sitc-2024

👍️ 1 😃 1

axelvento 2 months ago

back to the 23 November lows bounce spot watching either way to see if holds or breaks.

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Moderna Inc (MRNA)

Empower your portfolio: Real-time discussions and actionable trading ideas.

MRNA News

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

U.S. Futures Rise as Investors Await Fed Rate Decision; Oil Prices Drop

Trump Media Shares Surge 32% Pre-Market; Tesla Jumps 13%; Coinbase Rises with BTC All-Time High

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

Form 4 - Statement of changes in beneficial ownership of securities

Shareholders of Moderna, Inc. Should Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights - MRNA

MRNA Discussion

Your Recent History

Company

Business

Popular

Get The App

BLACK FRIDAY

Save up to 60%* for Canadian Securities Exchange (CSE) Level 1 and 2

1 year 40%, 2 years 40% and *3 years 60%

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Moderna Inc (MRNA) News

Moderna Inc (MRNA)

Empower your portfolio: Real-time discussions and actionable trading ideas.

MRNA News

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

U.S. Futures Rise as Investors Await Fed Rate Decision; Oil Prices Drop

Trump Media Shares Surge 32% Pre-Market; Tesla Jumps 13%; Coinbase Rises with BTC All-Time High

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

Form 4 - Statement of changes in beneficial ownership of securities

Shareholders of Moderna, Inc. Should Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights - MRNA

MRNA Discussion

Your Recent History

Company

Business

Popular

Get The App

BLACK FRIDAY

Save up to 60%* for Canadian Securities Exchange (CSE) Level 1 and 2

1 year 40%, 2 years 40% and *3 years 60%